🇺🇸 Pharmorubicin in United States

872 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Agranulocytosis — 172 reports (19.72%)
  2. Bone Marrow Failure — 122 reports (13.99%)
  3. White Blood Cell Count Decreased — 121 reports (13.88%)
  4. Hepatic Function Abnormal — 87 reports (9.98%)
  5. Nausea — 81 reports (9.29%)
  6. Vomiting — 77 reports (8.83%)
  7. Leukopenia — 76 reports (8.72%)
  8. Pyrexia — 50 reports (5.73%)
  9. Myelosuppression — 43 reports (4.93%)
  10. Neutrophil Count Decreased — 43 reports (4.93%)

Source database →

Pharmorubicin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Pharmorubicin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Pharmorubicin in United States?

Zhejiang Cancer Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.